Learn more about our upcoming Galas and Signature Events Learn More
Superyacht Captain, TV Personality, Melanoma Patient and Advocate Poised to Emcee Event Honoring the Melanoma Community New York City, NY (September 11, 2025) – The...
The MRF is proud to join our fellow members of the National Council on Skin Cancer Prevention (NCSCP) in urging the U.S. Food and Drug Administration (FDA) to finalize prop...
Guest blog post by Jamie Goldfarb, stage 4 melanoma survivor, clinical trial participant and melanoma advocate: I was diagnosed with stage 4 melanoma in January 2011. It...
Guest blog post by Katie Doble, ocular melanoma (OM) survivor, MRF Courage Award recipient and OM advocate: TIL therapy has given my family and me next-level hope. At 31 ye...
The Melanoma Research Foundation (MRF) is pleased to share recent significant achievements for the melanoma community. In March 2022, the U.S. Food and Drug Administration ...
On March 15, the U.S. Food and Drug Administration (FDA) granted Iovance Biotherapeutics, Inc. an Investigational New Drug Application (IND) for IOV-4001, its first geneti...
On February 25, 2022, the American Cancer Society Cancer Action Network (ACS-CAN) and the National Comprehensive Cancer Network (NCCN) sent a joint letter to the Majority a...
As the MRF observes Rare Disease Day on February 28, 2022, we celebrate the courageous and inspiring members of our community who are living with a rare melanoma subtype. M...
WASHINGTON, DC (February 23, 2022) – The Melanoma Research Foundation (MRF) will host nearly 100 advocates during the all-virtual MRF Advocacy Days held March 7-11, 2022....
Guest blog post by Monique Mack, “In the Sun” documentary participant, melanoma survivor and MRF advocate: My name is Monique Mack, and I am honored to be an advoca...
Guest blog post by Katonya Breaux, Founder, Unsun Cosmetics and MRF advocate: I discovered moles on my face that I thought were genetic, but after a visit to the dermato...
Guest blog post by Samantha Buirski, ocular melanoma patient, advocate and member of the CURE OM Patient Steering Committee: Being part of a rare community is challenging. ...
On January 26, 2022, the U.S. Food and Drug Administration announced the approval of KIMMTRAK (tebentafusp-tebn), the first and only FDA-approved treatment for metastatic u...
Oct 16, 2025 ET
Oct 30, 2025 ET
